TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20606239

Group type: EXPERIMENTAL
Intervention: Rib raising
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (light touch)
Number of subjects: 23
Study: 18253066

Group type: EXPERIMENTAL
Intervention: A. vera gel (97.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% hydrocortisone in placebo gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study: 15986873

Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week) for 12 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 154

Group type: COMPARATOR
Intervention: pegIFNalpha‐2a (180 microg/week) plus placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a
Number of subjects: 154
Study: 12643956

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting self-regulatory practices
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 365

Group type: COMPARATOR
Intervention: Usual-eye-care control group
Number of subjects: 365
Study: 10231302

Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography
Number of subjects: 102
Study: 8696717

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, escalated by 250 mg/m2/week to 1750 mg/m2) and Cisplatin (25 mg/m2 escalated to 30 mg/m2) administered as 30 min infusions weekly x 3 with a week of rest.
Number of subjects: 32
Study: 2062488

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 22
Study: 6133802

Group type: EXPERIMENTAL
Intervention: Azatadine maleate/pseudoephedrine sulfate syrup
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 28008096

Group type: EXPERIMENTAL
Intervention: Dry care umbilical cord method
Number of subjects: 8698

Group type: COMPARATOR
Intervention: Antiseptic care
Number of subjects: 8698
Study: 25498742

Group type: EXPERIMENTAL
Intervention: Abdominal massage administered twice daily for 15 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32
Study: 23323626

Group type: EXPERIMENTAL
Intervention: Local anaesthetic injection (bupivacaine) during banding
Number of subjects: 72

Group type: COMPARATOR
Intervention: No local anaesthetic injection (control)
Number of subjects: 72
Study: 20821330

Group type: EXPERIMENTAL
Intervention: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + pegylated liposomal doxorubicin (20 mg/m2 day 1 every two weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + mitomycin-C (7 mg/m2 every 6 weeks)
Number of subjects: 78
Study: 20006142

Group type: EXPERIMENTAL
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (5microg, 15microg or 45microg) with a 50microg LT adjuvant patch applied over the injection site
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Two-injection/two-patch 45microg HA regimen
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) with LT patch on second immunization
Number of subjects: 500

Group type: COMPARATOR
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) without LT patch
Number of subjects: 500
Study: 15734614

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 342

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 342
Study: 12788477

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin E
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10547405

Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard medical therapies
Number of subjects: 178
Study: 8690821

Group type: EXPERIMENTAL
Intervention: Continuous infusion of torsemide (75 mg over 24 hours with a 25 mg loading bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous bolus of torsemide (100 mg)
Number of subjects: 0
Study: 2062989

Group type: EXPERIMENTAL
Intervention: Midazolam (6.13 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diazepam (6.4 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both Midazolam and Diazepam
Number of subjects: 30
Study: 6342330

Group type: EXPERIMENTAL
Intervention: Moore hemiarthroplasty cemented with methyl methacrylate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Moore hemiarthroplasty noncemented prosthesis
Number of subjects: 29
Study: 31996543

Group type: EXPERIMENTAL
Intervention: Norepinephrine (8 μg bolus)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Phenylephrine (100 μg bolus)
Number of subjects: 102
Study: 30866887

Group type: EXPERIMENTAL
Intervention: Health check facilitated by trained lay advisors
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 246
Study: 30246750

Group type: EXPERIMENTAL
Intervention: Green tea mouthrinse
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic mouthrinse
Number of subjects: 40
Study: 26826108

Group type: EXPERIMENTAL
Intervention: Resin infiltration of proximal caries lesions
Number of subjects: 87

Group type: COMPARATOR
Intervention: Individualized noninvasive measures alone (Control)
Number of subjects: 87
Study: 24554246

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: C-Trach Laryngeal Mask Airway (C-Trach)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (Cobra PLA)
Number of subjects: 180
Study: 22294091

Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach (ALMI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Modified direct-lateral approach (mDL)
Number of subjects: 30
Study: 20122023

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0
Study: 17685710

Group type: EXPERIMENTAL
Intervention: Static stretching before workout
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static stretching after workout
Number of subjects: 30
Study: 16388091

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (without troglitazone)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Troglitazone and Control
Number of subjects: 12
Study: 12161056

Group type: EXPERIMENTAL
Intervention: Repaglinide (n=116, preprandially three-times daily)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Glibenclamide (n=119, preprandially once- or twice-daily)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 235
Study: 9447854

Group type: EXPERIMENTAL
Intervention: Desflurane without fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Isoflurane without fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Desflurane with 1.5 microg/kg fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Isoflurane with 1.5 microg/kg fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Desflurane with 3 microg/kg fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Isoflurane with 3 microg/kg fentanyl
Number of subjects: 71

Group type: COMPARATOR
Intervention: Desflurane and isoflurane without fentanyl
Number of subjects: 71
Study: 7819058

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms three times a day for 5 days a week)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 107
Study: 2194053

Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.05mg of buprenorphine (G-II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.25mg of morphine (G-III)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.25mg of morphine and 0.2mg of naloxone (G-IV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 7.5mg of dibucaine only (G-I)
Number of subjects: 50
Study: 348378

Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypercholesterolemic patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypertriglyceridemia type IV patients
Number of subjects: 30
Study: 31927569

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral therapy for insomnia (CBTi) over 4 weeks (n=72)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No-treatment control (n=73)
Number of subjects: 145
Study: 30986737

Group type: EXPERIMENTAL
Intervention: DROP programme (care management, optimised management of depression, psychoeducational programme)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: DROP programme
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 328
Study: 28649948

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) plus usual care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study: 25771069

Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril, 0.8 mg folic acid)
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril alone (10 mg)
Number of subjects: 20702
Study: 23585557

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exposure therapy, n = 7
Number of subjects: 15

Group type: COMPARATOR
Intervention: Imaginal Exposure (IE) therapy, n = 8
Number of subjects: 15
Study: 21755820

Group type: EXPERIMENTAL
Intervention: Platelet adhesion assay (PADA) in AMI patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Platelet adhesion assay (PADA) in SAP patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Platelet adhesion assay (PADA) in control group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Coronary angiography and stent implantation
Number of subjects: 104
Study: 18795264

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment with cognitive behavioral therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Naltrexone treatment
Number of subjects: 63
Study: 16757790

Group type: EXPERIMENTAL
Intervention: Spiritually based self-management tools
Number of subjects: 0
Study: 11860403

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 40
Study: 10442205

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 12
Study: 7568442

Group type: EXPERIMENTAL
Intervention: Smoking abstinence (16 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No smoking abstinence
Number of subjects: 20
Study: 1694236

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and daunorubicin (course one) followed by standard-dose cytarabine and daunorubicin (course two)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Azacitidine and doxorubicin (course one) followed by standard-dose cytarabine, daunorubicin, and thioguanine (course two)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine-based chemotherapy and/or allogeneic bone marrow transplantation (BMT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ALP3 postremission chemotherapy regimen
Number of subjects: 102
Study: 619938

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 0.2 mg intramuscularly
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (oral route)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (intravenous route)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (intramuscular route)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Larger doses of Glycopyrronium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (sweat gland activity)
Number of subjects: 6
Study: 29468701

Group type: EXPERIMENTAL
Intervention: 50 mg/d allopurinol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 100 mg/d allopurinol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patients who achieved primary endpoint
Number of subjects: 73
Study: 27471786

Group type: EXPERIMENTAL
Intervention: STAND
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WALK
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CYCLE
Number of subjects: 9

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 9
Study: 26282359

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study: 24418037

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline solution (n = 50)
Number of subjects: 100
Study: 20497967

Group type: EXPERIMENTAL
Intervention: Matuzumab plus ECX (800 mg matuzumab weekly, epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Number of subjects: 72

Group type: COMPARATOR
Intervention: ECX alone (epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Number of subjects: 72
Study: 18456138

Group type: EXPERIMENTAL
Intervention: Implant group
Number of subjects: 18

Group type: COMPARATOR
Intervention: J-hook headgear group
Number of subjects: 18
Study: 15920102

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (6.4% wt/vol) during exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA) beverage ingestion during exercise
Number of subjects: 15
Study: 12448067

Group type: COMPARATOR
Intervention: Atenolol (n = 28; dose 25 to 100 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Terazosin (n = 26; dose 1 to 10 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison of Atenolol vs Terazosin
Number of subjects: 54
Study: 9607387

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 to 10 mg once daily (n = 55)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nifedipine SR 20 mg twice daily (n = 48)
Number of subjects: 103
Study: 7883543

Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin administered 12 hours before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered 12 hours before surgery
Number of subjects: 40
Study: 2244403

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg tid
Number of subjects: 74

Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg tid
Number of subjects: 74
Study: 402206

Group type: EXPERIMENTAL
Intervention: Inguinal orchiectomy followed by irradiation to the inguinal, iliac, lumbar para‐aortic, mediastinal and supraclavicular lymph nodes.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative irradiation to primary lymphatic pathways in association with bilateral retroperitoneal lymphadenectomy and elective irradiation to the mediastinum and supraclavicular regions.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Both treatment methods (inguinal orchiectomy with irradiation and pre- and postoperative irradiation with lymphadenectomy)
Number of subjects: 91
Study: 31074245

Group type: EXPERIMENTAL
Intervention: Minimally-invasive secondary cytoreductive surgery (MI-SCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open secondary cytoreductive surgery (O-SCS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher cisplatin peritoneal Cmax
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower cisplatin peritoneal Cmax
Number of subjects: 20
Study: 28467880

Group type: EXPERIMENTAL
Intervention: Teprotumumab (administered intravenously once every 3 weeks for a total of eight infusions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (administered intravenously once every 3 weeks for a total of eight infusions)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 26106097

Group type: EXPERIMENTAL
Intervention: Theta burst stimulation of the fornix (200 Hz in 100 ms trains, five trains per second, 100 µs, 7 mA)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study: 24477039

Group type: EXPERIMENTAL
Intervention: White-wheat bread low in dietary fiber
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rye bread with whole-rye kernels
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White-wheat bread supplemented with wheat arabinoxylan
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White-wheat bread supplemented with oat β-glucan
Number of subjects: 21
Study: 22805083

Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CMG) - treated with Chinese medicine according to syndrome differentiation for 48 weeks.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Western medicine group (WMG) - treated with donepezil at a dose of 5 mg once daily for 48 weeks.
Number of subjects: 131
Study: 19910654

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2.4 g/d; 2,000 mg EPA, 400 mg DHA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17301105

Group type: EXPERIMENTAL
Intervention: Home testing kit
Number of subjects: 403

Group type: COMPARATOR
Intervention: Invitation to attend a medical clinic for testing
Number of subjects: 403
Study: 15151941

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 560
Study: 11190790

Group type: EXPERIMENTAL
Intervention: Negative priming (cognitive inhibition)
Number of subjects: 0
Study: 9845996

Group type: EXPERIMENTAL
Intervention: Counselling supervision group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study: 8087446

Group type: EXPERIMENTAL
Intervention: Amikacin and ceftazidime
Number of subjects: 166
Study: 31018727

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL (after matching)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard dressings (after matching)
Number of subjects: 179
Study: 30064450

Group type: EXPERIMENTAL
Intervention: Betaine (2.5 g/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 26937942

Group type: EXPERIMENTAL
Intervention: N2O (nitrous oxide) inhalation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 50
Study: 23962976

Group type: EXPERIMENTAL
Intervention: School-based psychosocial intervention
Number of subjects: 0
Study: 23345635

Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 12 mg/day for 20 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 17
Study: 20484125

Group type: EXPERIMENTAL
Intervention: Diabetes TeleCare (remote comprehensive diabetes self-management education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19707287

Group type: EXPERIMENTAL
Intervention: Various antithrombotic regimens (specific regimens not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant and antiplatelet agents (specific agents not detailed)
Number of subjects: 0
Study: 16813591

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for rectal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast-track open surgery
Number of subjects: 0
Study: 15566681

Group type: COMPARATOR
Intervention: EMBE
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EMBE and after-loading treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EMBE and RFA
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EMBE and PCS
Number of subjects: 49
Study: 11003070

Group type: EXPERIMENTAL
Intervention: Automated Auditory Brainstem Response (AABR)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Distortion‐Product Otoacoustic Emissions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Click‐Evoked Otoacoustic Emissions
Number of subjects: 105

Group type: COMPARATOR
Intervention: All tests
Number of subjects: 105
Study: 9048298

Group type: EXPERIMENTAL
Intervention: 6F Percuflex stent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6F HydroPlus stent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4.8F HydroPlus stent
Number of subjects: 60
Study: 8322572

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Methohexitone 2 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propofol (all doses)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Thiopentone and Methohexitone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 and 2.5 mg.kg‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Barbiturates (Thiopentone and Methohexitone)
Number of subjects: 123
Study: 3709070

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia of the upper airways
Number of subjects: 11

Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 11
Study: 31566918

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for childhood insomnia (CBT‐CI)
Number of subjects: 17
Study: 29772190

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TMJ TJR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dental implant placement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (volunteers without implanted metallic devices)
Number of subjects: 30